UroGen Pharma Ltd.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2018 | $-9.6M | $-9.7M | $72.0K | $4.5M |
| Jun 2018 | $-8.1M | $-8.3M | $132.0K | $7.7M |
| Sep 2018 | $-9.3M | $-9.6M | $332.0K | $9.5M |
| Dec 2018 | $-10.3M | $-10.3M | $24.0K | $8.9M |
| Mar 2019 | $-17.9M | $-18.0M | $44.0K | $7.4M |
| Jun 2019 | $-14.6M | $-14.6M | $40.0K | $7.2M |
| Sep 2019 | $-12.5M | $-12.6M | $49.0K | $7.2M |
| Dec 2019 | $-26.0M | $-26.2M | $192.0K | $8.1M |
| Mar 2020 | $-35.6M | $-35.7M | $96.0K | $7.6M |
| Jun 2020 | $-23.9M | $-24.2M | $287.0K | $7.1M |
| Sep 2020 | $-25.1M | $-25.7M | $660.0K | $6.8M |
| Dec 2020 | $-21.2M | $-21.4M | $172.0K | $6.5M |
| Mar 2021 | $-27.4M | $-27.7M | $287.0K | $6.2M |
| Jun 2021 | $-18.9M | $-19.0M | $69.0K | $6.0M |
| Sep 2021 | $-18.5M | $-18.7M | $194.0K | $5.5M |
| Dec 2021 | $-20.1M | $-20.3M | $202.0K | $5.4M |
| Mar 2022 | $-24.0M | $-24.0M | $25.0K | $2.9M |
| Jun 2022 | $-24.2M | $-24.3M | $63.0K | $2.8M |
| Sep 2022 | $-17.6M | $-17.8M | $153.0K | $2.4M |
| Dec 2022 | $-21.8M | $-21.8M | $13.0K | $2.4M |
| Mar 2023 | $-25.8M | $-25.8M | $23.0K | $2.3M |
| Jun 2023 | $-20.3M | $-20.3M | $15.0K | $2.2M |
| Sep 2023 | $-17.3M | $-17.4M | $100.0K | $2.2M |
| Dec 2023 | $-13.0M | $-13.1M | $56.0K | $2.6M |
| Mar 2024 | $-31.7M | $-31.7M | $0 | $2.8M |
| Jun 2024 | $-23.7M | $-23.8M | $84.0K | $3.6M |
| Sep 2024 | $-27.7M | $-27.8M | $96.0K | $3.5M |
| Dec 2024 | $-13.6M | $-13.7M | $115.0K | $3.3M |
| Mar 2025 | $-42.0M | $-42.1M | $44.0K | $3.1M |
| Jun 2025 | $-39.8M | $-40.0M | $141.0K | $2.7M |
| Sep 2025 | $-42.3M | $-42.4M | $87.0K | $3.0M |
| Dec 2025 | $-38.3M | $-38.3M | $17.0K | $3.1M |
| Mar 2026 | $-45.3M | $-45.4M | $54.0K | $4.6M |
| Jun 2026 | $-33.0M | $-33.1M | $60.0K | $5.3M |